ASH 2025 | GIMEMA ALL2820: ponatinib plus blinatumomab vs imatinib and chemotherapy for newly diagnosed Ph+ ALL
Sabina Chiaretti
• 6 Dec 2025
In this press briefing, Sabina Chiaretti, MD, PhD, University of Rome, Rome, Italy, shares the first results of the Phase III GIMEMA ALL2820 trial (NCT04722848) comparing ponatinib plus blinatumomab with imatinib and chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This press briefing took place at the 67th ASH Annual Meeting and Exposition, held in Orlando, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
